Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1134-1143, McCormack,M.,et al, 2011
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1126-1133, Chen,P.,et al, 2011
Mycophenolate Mofetil May Be Effective in CNS Sarcoidosis But Not in Sarcoid Myopathy
Neurol 76:1168-1172, Androdias,G.,et al, 2011
Lingual Hematoma After Thrombolytic Therapy
NEJM 364:e13, Vijayan,S. &Chase,A., 2011
Tumefactive Demyelination, an Uncommon Form of Tacrolimus Neurotoxicity
Neurol 76:672-674, Kim,S.H.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
Differential Diagnosis of Bilateral Abnormalities of the Basal Ganglia and Thalamus
RadioGraphics 31:5-30, Hegde,A.N.,et al, 2011
Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects
JAMA 305:1996-2002, Molgaard, D. & Hviid, A., 2011
Evidence-based guideline: Treatment of painful diabetic neuropathy
Neurol 76:1758-1765, Bril,V., et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Clinicopathologic Conference, Sjogrens syndrome with dorsal-root ganglionitis
NEJM 364:1856-1865, Case 14-2011, 2011
Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease
Neurol 76:1372-1376, Sone, J.,et al, 2011
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children
Neurol 76:1338-1343, Arya, R.,et al, 2011
Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis
Neurol 76:1288-1295, Tisserand, M.,et al, 2011
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
BMJ 342:d1938, McArthur, K.S.,et al, 2011
Clinicopathologic Conference, hemophagocytic lymphohistiocytosis
NEJM 364:1259-1270, Case 10-2011, 2011
VGKC antibodies in pediatric encephalitis presenting with status epilepticus
Neurology 76:1252-1255, Suleiman, J.,et al, 2011
Anticoagulation in Patients with Stroke With Infective Edocarditis Is Safe
Stroke 42:1795-1796,1799, Rasmussen, R.V., 2011
Anticoagulation Should Not Be Used in Most Patients With Stroke With Infective Endocarditis
Stroke 42:1797-1798,1799, Sila, C., 2011
Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss
JAMA 305(20):2071-2079,2114, Rauch, S.D.,et al, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics
Stroke 42:1771-1774, Tsivgoulis, G.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Clinical and MRI characteristics of acute migrainous infarction
Neurol 76:1911-1917, Wolf, M.E.,et al, 2011
Cannabis Use, Ischemic Stroke, and Multifocal Intracranial Vasoconstriction
Stroke 42:1778-1780, Wolff, V.,et al, 2011
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
Neurol 76:1555-1563, French, J.A.,et al, 2011
A Case of Hashimoto Encephalopathy Clinical Manifestation, Imaging, Pathology, Treatment, and Prognosis
The Neurologist 17:141-143, Zhao, W.,et al, 2011
Headache rate and cost of care following lumbar puncture at a single tertiary care hospital
Neurol 77:71-74, Dakka, Y.,et al, 2011
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Spontaneous Regression of an Intracerebral Lymphoma (ghost tumor) in a Liver-Engrafted Patient
The Neurologist 17:218-221, Korner, S.,et al, 2011
Cerebral Venous Sinus Thrombosis Associated with Cerebral Hemorrhage Is Anticoagulant Treatment Safe?
The Neurologist 17:208-210, Fuentes, B.,et al, 2011
Microbleeds are Associated with Subsequent Hemorrhagic and Ischemic Stroke in Healthy Elderly Individuals
Stroke 42:1867-1871, Bokura, H.,et al, 2011
Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke
Stroke 42:1967-1970, Sarikaya, H.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging
AJNR 32:984-992, Haldorsen, I.S.,et al, 2011
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
Lancet 377:2013-2022, Bousser, M.G.,et al, 2011